Abstract
Liver disease is an important complication of human immunodeficiency virus (HIV) infection. As HIV-infected patients live longer, they develop long-term manifestations of chronic HIV infection and/or treatment complications. Progressive liver disease is one of the leading causes of morbidity and mortality in this patient group. Underlying hepatitis B and/or C virus infection is extremely common. All classes of antiretroviral drugs have been associated with some hepatotoxicity, and patients often receive other potentially liver-damaging drugs. Alcohol use is common and frequently underestimated. All of these issues make liver disease an important factor in making antiretroviral decisions. Clinicians should weigh underlying disease, behavioral issues such as drugs and alcohol, and concomitant therapy when choosing antiretrovirals in such patients. We need more research in this area, especially with regard to mechanisms, risks, and management--for specific drugs and regimens--to ensure that our patients receive the benefits of antiretroviral therapy in the safest manner possible.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.